News Knight Therapeutics Inc. Deutsche Boerse AG

Equities

04K

CA4990531069

Market Closed - Deutsche Boerse AG Other stock markets 11:32:46 28/06/2024 am IST			5-day change	1st Jan Change
3.76 ^EUR	+0.53%		+2.17%	+6.82%

09/05	Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	MT
09/05	Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	09/05	MT
Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Knight Therapeutics Brief: Q1 Net loss was $4.546 Million; Revenues were $86.604 Million	09/05	MT
Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America	09/05	MT
Knight Therapeutics Reports First Quarter 2024 Results	09/05	GL
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America	09/05	GL
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024	09/05	CI
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for Jornay Pm® for Canada and Latin America	09/05	CI
Knight Therapeutics Inc. announces voting results from the Annual General Meeting	09/05	GL
Knight Therapeutics Inc. announces voting results from the Annual General Meeting	09/05	AQ
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City	07/05	GL
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call	02/05	GL
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04	GL
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity	28/03	GL
Knight Therapeutics Price Target Raised to $7 at RBC	22/03	MT
Knight Therapeutics Reports Fourth Quarter Results	21/03	MT
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024	21/03	CI
Transcript : Knight Therapeutics Inc., Q4 2023 Earnings Call, Mar 21, 2024	21/03
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Knight Therapeutics Inc. Deutsche Boerse AG

Equities

04K

CA4990531069

Summary

Filters